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Abstract
Adiponectin is an adipocyte-derived plasma protein that has been implicated in regulating angiogenesis, but the role of
adiponectin in regulating this process is still controversial. In this study, in order to determine whether adiponectin affects
tumor growth and tumor induced vascularization, we implanted B16F10 melanoma and Lewis Lung Carcinoma cells
subcutaneously into adiponectin knockout and wild-type control mice, and found that adiponectin deficiency markedly
promoted the growth of both tumors. Immunohistochemical analyses indicated that adiponectin deficiency reduced
macrophage recruitment to the tumor, but did not affect cancer cell mitosis, apoptosis, or tumor-associated angiogenesis.
In addition, treatment with recombinant adiponectin did not affect the proliferation of cultured B16F10 tumor cells.
Importantly, the restoration of microphage infiltration at an early stage of tumorigenesis by means of co-injection of B16F10
cells and macrophages reversed the increased tumor growth in adiponectin knockout mice. Thus, we conclude that the
enhanced tumor growth observed in adiponectin deficient mice is likely due to the reduction of macrophage infiltration
rather than enhanced angiogenesis.
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Introduction
Adiponectin, also named Acrp30, is an adipocyte-derived
plasma protein which plays an important role in regulating fat
and glucose metabolism. Serum levels of adiponectin are reduced
in obese individuals, and inversely correlate with several diseases,
including type II diabetes [1], cardiovascular diseases [2] and
metabolic syndromes [3], as well as the risk of developing multiple
types of cancers [4].
Although adiponectin has been suggested to be one of the
regulators of angiogenesis, its precise role in regulating this process
is still not clear. One group, employing in vitro cell culture systems
and other angiogenesis models, showed that adiponectin can
stimulate angiogenesis [5,6]. In addition, two recent papers [7,8]
demonstrated that adiponectin deficiency reduced primary tumor-
induced vascularization, indicating that adiponectin might be pro-
angiogenic. However, another study, using different models,
suggested that adiponectin is a negative regulator of angiogenesis
[9], which is also supported by a recent finding [10] that the
administration of adenovirus expressing adiponectin suppressed
liver tumor growth in nude mice by inhibiting angiogenesis. These
discrepancies may be due to the different experimental systems
employed in these studies.
In the present study, in order to determine the role of
adiponectin in tumor growth and tumor induced angiogenesis,
we investigated whether adiponectin deficiency has any effect on
the growth rate of tumor cells implanted in syngeneic and
immunocompetent mice. We found that the loss of adiponectin
significantly promoted tumor growth in vivo, but did not affect
tumor-associated vascularization. Mechanistic insights into this
phenotype suggest that adiponectin deficiency enhances tumor
growth in mice most likely by reducing macrophage infiltration.
Results
Adiponectin deficiency enhances primary tumor growth
but does not affect metastatic colonization
Adiponectin knockout mice in our lab were maintained in a
C57BL/6J background and both B16F10 melanoma cells and
Lewis Lung Carcinoma (LLC) cells were derived from the same
(C57BL/6J) background. In order to determine the role of
adiponectin in regulating tumor growth, we implanted B16F10
cells or LLC cells subcutaneously into adiponectin knockout (KO)
and control C57BL/6J (WT) mice. As shown in Figures 1A, B and
C, B16F10 and LLC tumor cells were able to grow in both
adiponectin KO and wild type (WT) mice. Notably, tumor cells
implanted in adiponectin KO mice grew more rapidly than those
implanted in WT mice; at 14 days post implantation, the average
tumor volume in adiponectin KO mice was approximately 3-fold
larger than that in control mice (Figures 1A and C, p,0.05).
At 14 days post implantation, the majority of B16F10 and LLC
tumors growing in adiponectin knockout mice were over 2 cm in
diameter, which met the euthanasia criteria in our animal
protocol. Therefore, we terminated these experiments at 2 weeks
after tumor cell implantation. No macroscopic lung metastases
were observed at this time point (data not shown). To determine
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ability of B16F10 cells, we injected the B16F10 cells into mice
through the tail vein, and did not observe a significant difference in
lung colonization between the adiponectin deficient mice and the
wild-type control animals, as quantified by counting lung nodules
in individual mice (Figure 1D, p.0.05).
Because previous reports have suggested that recombinant
adiponectin was able to inhibit the proliferation of cultured breast
cancer cell lines (MDA-MB-231 and MCF-7) [11,12], we
investigated whether recombinant adiponectin can also suppress
B16F10 cell proliferation in vitro. As shown in supplemental
Figure S1, although purified mouse recombinant adiponectin
could inhibit MDA-MB-231 cell proliferation at a concentration of
30 mg/ml, the same recombinant protein had no effect on B16F10
cell proliferation in vitro, suggesting that the inhibitory effects of
adiponectin on cell proliferation are cell-type dependent and that
other mechanisms by which adiponectin deficiency promotes
tumor growth in mice are yet to be identified.
Apoptosis, mitosis and angiogenesis are not affected but
macrophage recruitment to the tumor is reduced in the
absence of adiponectin
B16F10 and LLC tumor sections were analyzed 14 days after
cancer cell implantation. Immunohistochemical (IHC) analysis of
cleaved caspase 3 (Figure 2A and supplemental Figure S2A), a
marker for apoptotic cells; Ki-67 (Figures 2A, B and supplemental
Figures S2A, B), a marker for mitotic cells; and MECA-32
(Figures 2A, C and supplemental Figures S2A, C), an endothelial
cell maker, showed that adiponectin deficiency in mice had no
effect on tumor cell apoptosis, mitosis, or angiogenesis. Since
apoptotic cells were clustered throughout the tumors and unevenly
distributed, precise quantification was performed using FACS
analysis by annexin V and 7AAD staining (supplemental Figure
S3), which indicated no reduction in apoptosis in B16F10 tumors
from adiponectin null mice: at day 9, the percentage of apoptotic
cells in B16F10 tumors was 8.4263.62% (n=6) in wild-type mice
and 7.7863.21% in knock out mice (n=5, p=0.77).
Since accumulating evidence [13,14,15,16] has demonstrated
that adiponectin may modulate macrophage functions, and since
macrophages are involved in regulating tumor growth and
progression, we decided to examine the degree of macrophage
infiltration by immunohistochemical staining with the anti-F4/80
antibody, which recognizes a specific macrophage antigen. To
avoid experimenter bias, immunohistochemical analysis and
counting were conducted by an independent person blinded to
the adiponectin status. As shown in Figure 3A and supplemental
Figure S4A, macrophage infiltration was observed within the
tumors growing in adiponectin KO and WT mice. Although the
distribution of macrophages within each tumor was uneven and
more microphage infiltration was observed at the edge of tumors,
there was a clear reduction in macrophage recruitment to tumors
from adiponectin deficient mice than those from wild-type mice
(Figure 3A and supplemental Figure S4A). Microscopic examina-
tion revealed that the infiltration of macrophages was reduced by
Figure 1. Enhanced tumor growth in adiponectin-deficient mice. (A) Tumor volume of B16F10 melanoma cells in adiponectin knockout (KO)
mice and wild-type (WT) control mice as a function of time. (KO, n=10; WT n=6. *: p,0.05). (B) Photograph of B16F10 tumors dissected 14 days after
the injection (scale bar =10 mm). (C) Tumor volume of Lewis Lung Carcinoma (LLC) cells in adiponectin KO mice and WT control mice as a function of
time. (KO, n=8; WT n=7. #:p ,0.05) (D) Total numbers of metastatic nodules in the lung of individual WT or adiponectin KO mice. (KO, n=7; WT
n=13. p.0.05)
doi:10.1371/journal.pone.0011987.g001
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and supplemental Figure S4B, p,0.05). The numbers of
circulating B, T cells, granulocytes and monocytes were not
significantly altered in adiponectin KO mice (supplemental Figure
S5). Therefore, we concluded that the infiltration of macrophages
into the tumor was specifically decreased in adiponectin null mice.
Co-implantation of macrophages with B16F10 cells
reverses the observed increase in tumor growth in
adiponectin KO mice
Based on these observations, we hypothesized that macrophages
might play an inhibitory role in tumor growth in the tumor models
used in the present study. Macrophages are considered to be
highly phagocytic, essential immune effector cells that are derived
from monocytes that leave the blood, enter tissues, and
differentiate. Tumor associated macrophages (TAMs) are one of
the key regulators that link inflammation and cancer. Accumulat-
ing evidence suggests that TAMs display substantial phenotypic
heterogeneity and may play a dual role in tumor growth [17]: they
can be tumoricidal [18,19] at the early stages of tumorigenesis through
macrophage-mediated cytotoxicity [20] and phagocytosis [18]. On
the other hand, TAMs can be educated by the tumor microenvironment
and are capable of producing a number of angiogenic growth
factors, cytokines, and proteases, which may promote tumor
progression and metastasis [21].
In order to determine whether macrophages can reverse the
enhanced tumor growth in adiponectin KO mice, we wished to
restore macrophages to these tumors. To this end, we took
advantage of a well-established protocol that utilizes sterile eliciting
agents to recruit immature macrophages into the mouse peritoneal
cavity, resulting in an approximately 10 times increased yield of
macrophages [22]. Among various eliciting agents, we chose Bio-
Gel polyacrylamide beads because these beads cannot be
phagocytosed. Therefore, Bio-Gel-elicited macrophages are free
of intracellular debris, making these cells suitable for studies
pertaining to phagocytosis [22]. Using this agent we purified
murine peritoneal macrophages which contained 8–10% mature
macrophages and 60–70% immature macrophage (supplemental
Fig. S6).
Next, we co-injected B16F10 cells and freshly isolated and
characterized mouse peritoneal macrophages (supplemental Fig-
ure S6) subcutaneously into adiponectin knockout and wild-type
mice. This would mimic the restoration of macrophage recruitment
at the early stage of tumorigenesis. As shown in Figure 4, tumors
grew in both adiponectin knockout and wild-type mice after co-
injection of B16F10 cells and macrophages. However, tumor size
after co-injection of macrophages was significantly reduced in
adiponectin null mice (p,0.05) but not in wild-type mice. After 14
days post implantation, the average tumor volume was reduced by
as much as 2–3 fold in adiponectin knockout mice, resulting in
tumors similar in size to those growing in wild-type host animals
(Figure 4, p,0.05).
Discussion
To our knowledge the present study is the first that utilizes a
syngeneic, immunocompetent mouse model to investigate the
growth of transplanted tumor cells in an adiponectin deficient
background. Our data clearly show that adiponectin plays a role in
the suppression of the growth of implanted B16F10 melanoma and
Lewis Lung Carcinoma tumors, most likely by enhancing the
recruitment of macrophages to the tumor. We conclude that the
increased tumor growth observed in adiponectin deficient mice is
at least partly due to the reduction of macrophage infiltration and
not by enhanced angiogenesis.
Recombinant adiponectin inhibits proliferation of breast cancer
cell lines (MDA-MB-231 and MCF-7) in vitro[11,12], suggesting
that adiponectin may act as a cytokine which can directly suppress
tumor growth in vivo. However, our data showed that recombi-
nant adiponectin has no effect on the proliferation of cultured
B16F10 cells, indicating that the inhibitory effects of adiponectin
on cell proliferation are cell-type specific. This may be due to the
distinct expression of the adiponectin receptor and/or different
signal transduction pathways in various tissue types or even
different cell lines of the same tissue type. There are three putative
adiponectin receptors, adipoR1, adipoR2 [23] and T-cadherin
[24] but it is unclear whether they can transmit adiponectin
signals. AdipoR1 and AdipoR2 belong to the family of seven-
trans-membrane spanning receptors with the N terminus intra-
cellular, but the extracellular portion of these two receptors is small
which is distinct from members of seven-spanning that bind
peptide hormones. Although T-cadherin can bind adiponectin, it
is likely not a signaling receptor since T-cadherin does not contain
any trans-membrane domains. Thus, further identification of the
functional adiponectin signaling receptor(s) should shed light on
the role of adiponectin in glucose and fat metabolism and tumor
biology.
A few recent reports addressed the growth of primary tumors in
adiponectin knockout mice. For example, using a carcinogen
induced colorectal cancer model, Nishihara et al. [25] showed that
adiponectin knockout mice developed larger colorectal tumors.
There are at least two possible explanations of this result. First, as
indicated in the paper [25], tumor cells grew faster in adiponectin
knockout mice. Second, the latency of colorectal tumors developed
in adiponectin knockout mice might be shorter than in wild type
mice. Thus, by 53 weeks after the carcinogen treatment, tumors in
adiponectin knockout mice might exist longer and grow bigger
than those developed in wild-type mice. However, this possibility
was not discussed in the paper [25].
Primary MMTV-PyMT tumors grew faster in adiponectin
haploinsufficient mice than in wild-type mice [26]. However, the
tumor cells isolated from adiponectin haploinsufficient mice
showed accelerated proliferation in culture, indicating that these
cells are different from those isolated from wild-type mice.
Paradoxically, utilizing the same cancer model, two other groups
[7,8] showed that adiponectin plays a pro-angiogenic role and may
be pro-tumorigenic. Employing in vitro cell culture systems or in
vivo administration of recombinant adiponectin or adenovirus that
expresses adiponectin, several reports suggest that adiponectin
may suppress the growth of other types of tumors [9,12,27,28]
although the underlying mechanisms may be different. Collec-
tively, adiponectin is not only implicated in regulating glucose and
fat metabolism, but also is capable of regulating the growth of
multiple types of tumors, suggesting that adiponectin or its
Figure 2. B16F10 tumors from adiponectin knockout (KO) mice display similar apoptosis, mitosis and angiogenesis compared with
those from wild type (WT) mice. A. Immunohistochemistry staining of B16F10 tumor sections from wild type and adiponectin knockout mice.
Antibodies: cleaved caspase 3, Ki-67 and MECA-32 (vessels are brown and indicated by arrows. scale bar, 50 mm). B. Percentage of mitotic cells does
not change in tumors from adiponectin null mice (Fields counted: WT, n=5; KO, n=5. p.0.05). C. Adiponectin deficiency does not affect vessel
density in transplanted tumors (Fields counted: WT, n=17; KO, n=24. p.0.05).
doi:10.1371/journal.pone.0011987.g002
Acrp30 Inhibits Tumor Growth
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e11987Figure 3. Macrophage infiltration is reduced in B16F10 tumors from adiponectin knockout (KO) mice. A. Immunohistochemistry
staining of B16F10 tumor sections from wild type (WT) and adiponectin knockout (KO) mice against an anti-macrophage antibody F4/80. A lower
infiltration of macrophages (brown, indicated by black arrows; red arrows indicate the macrophage infiltration on the edge of tumors) was observed
in tumors grown in adiponectin null mice. (Scale bar, A: 200 mm, B: 50 mm). B. Microscopic counts indicate that adiponectin deficiency decreases intra-
tumor macrophage infiltration (Fields counted: WT, n=17; KO n=23; p,0.05).
doi:10.1371/journal.pone.0011987.g003
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agent.
In our study, adiponectin knockout mice exhibited normal
numbers of circulating monocytes but markedly reduced infiltrat-
ing macrophages within the tumors. This indicates that adipo-
nectin deficiency does not lead to monocyte defects, but instead
impairs the recruitment of macrophages to tumor tissues. The
mRNA expression of cytokines and growth factors, including
MCP1(CCL2), TNFa, IL12, IFNc, HGF, TGFb1 and FasL, in
tumors from adiponectin KO mice was similar to those from WT
mice (data not shown). Thus, the underlying mechanisms still
warrant further investigation. Strikingly, restoration of macro-
phages at the early stage of tumorigenesis by means of co-injection
of macrophages completely reversed the increase in tumor growth
in adiponectin null mice, while having little effect on tumor growth
in wild-type recipients. This suggests that in the models used here
adiponectin deficiency promotes tumor growth most likely by
reducing macrophage infiltration. Our findings support the notion
that macrophages can exert inhibitory effects on tumor growth at
early stages of tumorigenesis, and provide an explanation for the
association between low adiponectin levels and increased risk of
many cancers. Future work is needed to dissect the precise roles
and mechanisms of adiponectin in regulating tumorigenesis using
various model systems; these experiments may help to shed light
on the molecular basis through which obesity increases the risk for
cancer formation and progression.
Materials and Methods
Mice
All animal experimental protocols were approved by the
Committee on Animal Care of Massachusetts Institute of
Technology (Protocol number: 1107-086-10). Adiponectin knock-
out mice were generously provided by Dr. Matsuzawa [31], and
maintained in a C57BL/6J background.
Cell lines and cell culture
Murine B16F10 melanoma and Lewis Lung Carcinoma cells
were purchased from American Type Culture Collection (Man-
assas, Virginia). Human breast cancer cell line, MDA-MB-231,
was obtained from the Weinberg Lab (Whitehead Institute for
Biomedical Research, Cambridge, Massachusetts). All cell lines
were maintained in DMEM supplemented with 10% fetal bovine
serum, 2 mmole/L L-glutamine and penicillin-streptomycin, at
37uC in a humidified atmosphere of 5% CO2.
Murine peritoneal macrophages were isolated by p-100 Bio-Gel
polyacrylamide beads (Bio-Rad laboratories, Hercules, California)
elicitation [22]. Briefly, 1 ml sterile 2% (v/v) Bio-Gel suspension
was injected into the peritoneal cavity of WT mice. 4 days later,
elicited cells were recovered from the peritoneal fluids. Red blood
cells were removed using RBC lysis buffer (eBioscience, San
Diego, California), and the beads and other large particles were
removed by filtering through the 20 mm sterile cell strainer.
Mouse tumor cell transplantation
Six- to 8-week-old mice were injected subcutaneously on the
back with 1610
6 B16F10 cells (with or without 2610
6 freshly
isolated murine peritoneal macrophages), or 1610
6 Lewis Lung
Carcinoma cells in 100 ml of DMEM containing 50% Matrigel
(BD Biosciences, San Jose, California) [32]. Each group contains 5
to 10 mice. Tumor diameter was measured every 3 days, and
tumor volume was calculated as (H6W
2)/2.
Experimental metastasis assay
Sub-confluent B16F10 melanoma cells were washed with PBS
and detached by brief exposure to 0.25% trypsin and 0.2%
EDTA. Cells were washed twice with PBS and resuspended in
PBS at 1610
6 cells/ml. 100 ml mouse tumor cell suspension was
injected to the lateral tail vein of mice. Ten days after the injection,
lungs were harvested, and total numbers of metastatic nodules in
the lung of individual mice were counted under a dissecting
microscope.
Immunohistochemistry
Tumors were harvested from CO2-euthanized mice and fixed in
10% neutral buffered formalin. 4-5 micrometer paraffin-embed-
ded sections of tumors were used for immunohistochemistry.
Immunohistochemical staining of tumor sections against antibod-
ies anti-cleaved caspase 3, anti-Ki-67, anti-MECA-32 and anti-
F4/80 was performed by the core facility of the Division of
Comparative Medicine (Massachusetts Institute of Technology,
Cambridge, Massachusetts).
Vessel density in tumors was determined by anti-MECA-32
IHC staining. Briefly, any MECA-32+ endothelial cell or cell
cluster that was separated from adjacent micro-vessels was counted
as one vessel. The vessel density was expressed as the absolute
number of micro-vessels per field (1006field).
Intra-tumor macrophage infiltration was quantified by anti-F4/
80 IHC staining. Any F4/80+ stained mononuclear cell was
Figure 4. Macrophages can suppress tumor growth in adiponectin deficient mice. Tumor volume of B16F10 melanoma cells in
adiponectin-knockout (KO) mice and wild-type (WT) control mice 14 days after the subcutaneous injection of B16F10 melanoma cells together with
or without peritoneal macrophages (-macrophages: WT n=7 and KO n=8; +Macrophages: WT n=8 and KO n=8. #:p ,0.05).
doi:10.1371/journal.pone.0011987.g004
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expressed as the absolute number of macrophages per field (2006
field). 3 fields/section from non-necrotic regions in 3–8 tumors
were counted in a blinded fashion.
Flow cytometry
FITC-conjugated anti-F4/80 and PE-conjugated anti-CD11b
(eBioscience, San Diego, California) antibodies were used to
determine the purity of peritoneal monocytes. FITC-conjugated
anti-CD19, PE-conjugated anti-CD11b, APC-conjugated anti-
CD3 and PE-cy7-conjugated anti-Gr-1 (eBioscience, San Diego,
California) were used to stain B cells, T cells, monocytes and
granulocytes present in the blood of mice. Fractions of apoptotic
cells in transplanted B16F10 tumors were determined by FACS
using an Annexin V: PE Apoptosis Detection Kit (BD Biosciences,
San Jose, California).
Statistical analysis
Data are presented as mean 6 standard error and by unpaired
two-tailed Student’s t test. P values of ,0.05 were regarded as
statistically significant.
Supporting Information
Figure S1 Recombinant adiponectin does not affect B16F10 cell
proliferation. 50,000 cells per well are seeded into 6-well plate in
the presence or absence of 30 ug/ml recombinant adiponectin.
Cell numbers were counted at 24 hours or 48 hours (B16F10: 4
replicates per group; MDA-MB-231: 3 replicates per group.
*: p,0.05). Mouse recombinant adiponectin was expressed in
HEK293 cells.
Found at: doi:10.1371/journal.pone.0011987.s001 (0.17 MB TIF)
Figure S2 LLC tumors from adiponectin knockout (KO) mice
display similar apoptosis, mitosis and angiogenesis compared with
those from wild type (WT) mice. A. Immunohistochemistry
staining of LLC tumor sections from wild type and adiponectin
knockout mice. Antibodies: cleaved caspase 3, Ki-67 and MECA-
32 (vessels are brown and indicated by arrows. scale bar, 50 um).
B. Percentage of mitotic cells does not change in tumors from
adiponectin null mice (Fields counted: WT, n=4; KO, n=4.
p.0.05). C. Adiponectin deficiency does not affect vessel density
in transplanted tumors (Fields counted: WT, n=7; KO, n=10.
p.0.05).
Found at: doi:10.1371/journal.pone.0011987.s002 (3.59 MB
TIF)
Figure S3 FACS analysis of apoptosis in B16F10 tumors from
adiponectin null (KO) and wild type (WT) mice. B16F10 tumors
were harvested 9 days after cancer cell implantation. Then,
B16F10 cells were resuspended by pipetting up and down, and
strained through the 70 um cell drainer. The percentage of
apoptotic cells in transplanted B16F10 tumors were determined by
FACS using an Annexin V : PE Apoptosis Detection Kit (BD
Biosciences, San Jose, California).
Found at: doi:10.1371/journal.pone.0011987.s003 (0.10 MB TIF)
Figure S4 Macrophage infiltration is reduced in LLC tumors
from adiponectin knockout (KO) mice. A. Immunohistochemistry
staining of LLC tumor sections from wild type (WT) and
adiponectin knockout (KO) mice against an anti-macrophage
antibody F4/80. A lower infiltration of macrophages (brown,
indicated by black arrows; red arrows indicate the macrophage
infiltration on the edge of tumors) was observed in tumors grown
in adiponectin null mice. (Scale bar, A: 200 um, B: 50 um).
B. Microscopic counts indicate that adiponectin deficiency
decreases intra-tumor macrophage infiltration (Fields counted:
WT, n=9; KO n=9; p,0.05).
Found at: doi:10.1371/journal.pone.0011987.s004 (4.37 MB TIF)
Figure S5 Adiponectin deficiency does not alter monocyte
(CD11b+Gr-1-), granulocyte (CD11b+Gr-1+), T cells (CD3+) and
B cell (CD19+) number in peripheral blood. (adiponectin knockout
mice (KO), n=11; wild type mice (WT), n=9. p.0.05).
Found at: doi:10.1371/journal.pone.0011987.s005 (0.17 MB TIF)
Figure S6 FACS analysis of the purity of peritoneal macro-
phages. (Macrophage, F4/80+CD11b+; immature macrophage,
F4/80-CD11b+, n=4).
Found at: doi:10.1371/journal.pone.0011987.s006 (0.30 MB TIF)
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